By Chuck Mikolajczak
NEW YORK (Reuters) - U.S. stocks were flat in early trading Monday as gains in drugmaker Merck were offset by investor concern over valuations.
Investor concern may be increasing as stocks have become expensive, with the S&P above the mean forward price-to-earnings ratio and at its highest level in nearly seven years. The benchmark S&P 500 surged almost 30 percent in 2013.
According to Thomson Reuters data, fourth-quarter earnings are expected to grow 7.3 percent over the year-ago period. However, the 9.8 ratio of negative guidance to positive outlooks is currently the largest on record.
"It may be that people are speculating that is it is not going to be a very good season at this point," said Peter Jankovskis, co-chief investment officer at OakBrook Investments LLC in Lisle, Illinois.
Also Read
"The last three earnings seasons, people have been questioning how much more earnings improvement can we get without revenue improvement, and it may be that is finally catching up with companies."
Gains in Merck, up 2.9 percent to $51.33, the biggest boost to both the Dow and S&P 500, helped limit declines. A preliminary review by the U.S. Food and Drug Administration said the company's experimental blood clot-preventing drug vorapaxar should be approved. In addition, the drugmaker said it is pursuing strategic options for its animal health and consumer businesses and expects to complete any action it takes this year.
Earnings are expected from 29 companies in the S&P 500 this week, including banks such as Morgan Stanley
Results are also due from First Horizon National Corp
The Dow Jones industrial average rose 3.54 points or 0.02 percent, to 16,440.59, the S&P 500 <.SPX> lost 0.01 points or -0 percent, to 1,842.36 and the Nasdaq Composite added 1.591 points or 0.04 percent, to 4,176.255.
Equities have started 2014 on a lackluster note, dipping 0.3 percent through the first seven trading sessions as market participants try to gauge the pace of the winding down of market-friendly economic stimulus by the Federal Reserve.
Beam Inc
A string of companies tumbled after forecasting earnings.
Lululemon Athletica Inc
Sodastream International
But Wendy's
British engineering firm Amec
(Editing by Bernadette Baum and Nick Zieminski)


